Published in Adv Drug Deliv Rev on August 11, 2009
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J (2011) 1.70
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res (2011) 1.25
Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc Natl Acad Sci U S A (2012) 1.20
Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin Cancer Res (2011) 1.04
Removing T-cell epitopes with computational protein design. Proc Natl Acad Sci U S A (2014) 0.99
Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther (2010) 0.95
A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J Neurooncol (2010) 0.91
Immunogenicity of therapeutic recombinant immunotoxins. Immunol Rev (2016) 0.88
Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice. Blood (2012) 0.88
Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs. Curr Opin HIV AIDS (2011) 0.86
Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin. Protein Sci (2013) 0.84
Design and engineering of deimmunized biotherapeutics. Curr Opin Struct Biol (2016) 0.82
High-throughput sequencing enhanced phage display enables the identification of patient-specific epitope motifs in serum. Sci Rep (2015) 0.81
Towards engineering hormone-binding globulins as drug delivery agents. PLoS One (2014) 0.78
A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model. Pancreas (2012) 0.78
Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu. Mol Cancer Ther (2013) 0.78
Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism. Curr Top Med Chem (2014) 0.77
Site-Specific PEGylation of Therapeutic Proteins. Int J Mol Sci (2015) 0.76
A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead. Protein Eng Des Sel (2016) 0.75
Regulation of Subunit-Specific Germinal Center B Cell Responses to the HIV-1 Envelope Glycoproteins by Antibody-Mediated Feedback. Front Immunol (2017) 0.75
CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL. Biomedicines (2017) 0.75
Clinical targeting recombinant immunotoxins for cancer therapy. Onco Targets Ther (2017) 0.75
The interpretation of protein structures: estimation of static accessibility. J Mol Biol (1971) 40.24
VARIATIONS IN AFFINITIES OF ANTIBODIES DURING THE IMMUNE RESPONSE. Biochemistry (1964) 11.48
Germinal centers. Annu Rev Immunol (1994) 10.85
High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science (1989) 8.73
The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity (1994) 6.18
Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov (2008) 4.32
Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (1986) 4.19
Immunotoxin therapy of cancer. Nat Rev Cancer (2006) 3.93
Antibody-antigen complexes. Annu Rev Biochem (1990) 3.91
T cell-dependent B cell activation. Annu Rev Immunol (1993) 3.81
Correlation between segmental mobility and the location of antigenic determinants in proteins. Nature (1984) 3.66
Intrinsic and extrinsic factors in protein antigenic structure. Science (1985) 3.54
Humoral immune responses in CD40 ligand-deficient mice. J Exp Med (1994) 3.32
Epitopes on protein antigens: misconceptions and realities. Cell (1990) 3.32
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A (1984) 3.32
Continuous and discontinuous protein antigenic determinants. Nature (1986) 3.26
Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci (2006) 3.06
Differences in immune elimination in inbred mice. The role of low affinity antibody. Clin Exp Immunol (1972) 3.03
The design and implementation of the immune epitope database and analysis resource. Immunogenetics (2005) 3.00
Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Sci (2004) 2.70
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med (2001) 2.65
Immunotoxin treatment of cancer. Annu Rev Med (2007) 2.36
Production of functional chimaeric mouse/human antibody. Nature (1985) 2.35
A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol (2007) 2.35
Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci U S A (1996) 2.34
Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther (2002) 2.33
ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics (2008) 2.26
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol (2005) 2.16
Prediction of linear B-cell epitopes using amino acid pair antigenicity scale. Amino Acids (2007) 2.06
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal (2008) 2.05
Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit (2007) 2.02
Chemistry of antibody binding to a protein. Science (1987) 1.82
Epitome: database of structure-inferred antigenic epitopes. Nucleic Acids Res (2006) 1.70
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A (2008) 1.66
Integrating epitope data into the emerging web of biomedical knowledge resources. Nat Rev Immunol (2007) 1.59
Comparing antigenicity and immunogenicity of engineered gp120. J Virol (2005) 1.50
High resolution functional analysis of antibody-antigen interactions. J Mol Biol (1992) 1.49
Predicting location of continuous epitopes in proteins from their primary structures. Methods Enzymol (1991) 1.48
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol (2006) 1.42
A quantitative assessment of heterogeneity for surface-immobilized proteins. Anal Chem (2001) 1.40
A machine-learning approach for predicting B-cell epitopes. Mol Immunol (2008) 1.40
Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires. J Mol Recognit (2004) 1.22
Patterns of antibody specificity during the BALB/c immune response to hen eggwhite lysozyme. J Immunol (1992) 1.21
Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol (2006) 1.21
What is a B-cell epitope? Methods Mol Biol (2009) 1.18
Antigenicity and immunogenicity of synthetic peptides. Biologicals (2002) 1.17
MHC class II-restricted antigen processing and presentation. Adv Immunol (2000) 1.16
Dissecting the energetics of an antibody-antigen interface by alanine shaving and molecular grafting. Protein Sci (1994) 1.13
Epitope mapping by phage display: random versus gene-fragment libraries. J Immunol Methods (1997) 1.08
The physical and functional behavior of capture antibodies adsorbed on polystyrene. J Immunol Methods (1992) 1.05
Reduced antibody response to streptavidin through site-directed mutagenesis. Protein Sci (2001) 1.05
FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood (2007) 1.03
Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J Immunol Methods (2003) 1.02
Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm (2003) 1.02
Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens. Proc Natl Acad Sci U S A (2000) 1.02
Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev Technol (2007) 1.02
Caveats for the use of surface-adsorbed protein antigen to test the specificity of antibodies. J Immunol Methods (1992) 1.00
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol (2006) 1.00
Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther (2007) 0.98
Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther (2004) 0.94
Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood (2000) 0.93
Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. Circulation (1996) 0.93
Reductionism and the search for structure-function relationships in antibody molecules. J Mol Recognit (2002) 0.93
Recombinant immunotoxins for treating cancer. Int J Med Microbiol (2004) 0.90
Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br J Cancer (2004) 0.89
Prediction of linear B-cell epitopes. Methods Mol Biol (2009) 0.89
Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins. Thromb Haemost (2008) 0.89
Multiple overlapping epitopes in the three antigenic regions of horse cytochrome c1. J Immunol (1987) 0.89
Botulinum toxin: from life-threatening disease to novel medical therapy. Am J Obstet Gynecol (2007) 0.88
T and B cell cooperation: a dance of life and death. Transplantation (2005) 0.87
Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay. J Immunol Methods (2004) 0.86
B cell epitope mapping using synthetic peptides. Curr Protoc Immunol (2004) 0.85
Assessment of heterogeneity in antibody-antigen displacement reactions. Anal Chem (1997) 0.84
Foreignness as a matter of degree: the relative immunogenicity of peptide/MHC ligands. J Theor Biol (2004) 0.84
B-cell tolerance. Transplantation (2006) 0.83
Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy. Proc Natl Acad Sci U S A (2005) 0.81
Hierarchic T-cell help to non-linked B-cell epitopes. Scand J Immunol (1996) 0.81
Immunogenicity in peptide-immunotherapy: from self/nonself to similar/dissimilar sequences. Adv Exp Med Biol (2008) 0.81
Epitope mapping by antibody competition. Methodology and Evaluation of the validity of the technique. Methods Mol Biol (1996) 0.81
Clinical perspectives and therapeutics of thrombolysis. Int J Cardiol (2003) 0.80
B lymphocyte recognition of the self antigen mouse cytochrome C in different mouse strains: targeting of the same dominant epitope by naturally-occurring cells expressing distinct VH genes. Mol Immunol (1998) 0.79
Determination of epitope specificities of a large number of monoclonal antibodies by solid-phase mutual inhibition assays using biotinylated antigen. Immunol Invest (1992) 0.78
Intersite helper function of T cells specific for a protein epitope that is not recognized by antibodies. Immunol Invest (1997) 0.78
Potential use of shared antigens for immunization against gram-negative bacillary infections. Prog Clin Biol Res (1980) 0.78
Antigen presentation by B lymphocytes: mechanisms and functional significance. Semin Immunol (1989) 0.77
The influence of antibody functional affinity on the effector functions involved in the clearance of circulating immune complexes anti-BSA IgG/BSA. Immunol Invest (1999) 0.76
Immunogenicity of biotherapeutics-an overview. J Immunotoxicol (2006) 0.76
On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb Haemost (1994) 0.76
The role of calcitonin treatment in postmenopausal osteoporosis. Orthop Rev (1992) 0.76
Protein therapeutics--lessons learned and a view of the future. Expert Opin Biol Ther (2006) 0.76
Studies on the control of antibody synthesis. IX. Effect of boosting on antibody affinity. J Immunol (1975) 0.76
Valency or wählency: is the epitope diversity of the B-cell response regulated or chemically determined? Immunol Cell Biol (2001) 0.75
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Mesothelin: a new target for immunotherapy. Clin Cancer Res (2004) 4.30
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res (2007) 3.30
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer (2006) 2.70
Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol (2012) 2.58
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol (2005) 2.33
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res (2002) 2.30
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res (2009) 2.17
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol (2005) 2.16
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol (2012) 2.15
Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria. Kidney Int (2008) 2.14
Mesothelin expression in human lung cancer. Clin Cancer Res (2007) 2.10
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res (2005) 2.05
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun (2007) 2.00
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res (2006) 1.99
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol (2009) 1.86
Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol (2005) 1.84
Distinct roles of segregated transmission of the septo-habenular pathway in anxiety and fear. Neuron (2013) 1.78
Podocyte injury damages other podocytes. J Am Soc Nephrol (2011) 1.75
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery (2007) 1.74
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood (2008) 1.74
Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res (2008) 1.71
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J (2011) 1.70
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A (2008) 1.66
Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res (2004) 1.65
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res (2010) 1.64
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol (2008) 1.59
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res (2010) 1.59
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res (2006) 1.57
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem (2004) 1.54
Mice are unable to endogenously regenerate podocytes during the repair of immunotoxin-induced glomerular injury. Nephrol Dial Transplant (2013) 1.54
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res (2011) 1.54
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol (2007) 1.52
Mesothelin-targeted agents in clinical trials and in preclinical development. Mol Cancer Ther (2012) 1.47
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res (2007) 1.47
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A (2012) 1.44
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci U S A (2012) 1.42
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol (2006) 1.42
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A (2007) 1.41
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol (2007) 1.39
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res (2005) 1.39
Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. Proc Natl Acad Sci U S A (2003) 1.39
Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proc Natl Acad Sci U S A (2006) 1.37
Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. Cancer Res (2008) 1.34
Immunotoxins for leukemia. Blood (2014) 1.33
HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res (2005) 1.32
Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci U S A (2006) 1.30
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A (2011) 1.29
Permanent genetic tagging of podocytes: fate of injured podocytes in a mouse model of glomerular sclerosis. J Am Soc Nephrol (2005) 1.28
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther (2012) 1.27
Conditional ablation of striatal neuronal types containing dopamine D2 receptor disturbs coordination of basal ganglia function. J Neurosci (2003) 1.27
NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate. Proc Natl Acad Sci U S A (2004) 1.25
POTE, a highly homologous gene family located on numerous chromosomes and expressed in prostate, ovary, testis, placenta, and prostate cancer. Proc Natl Acad Sci U S A (2002) 1.25
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res (2011) 1.25
Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev (2006) 1.24
Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol Cell Biol (2010) 1.23
Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins. Proc Natl Acad Sci U S A (2003) 1.22
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res (2010) 1.21
Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc Natl Acad Sci U S A (2012) 1.20
Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice. J Nucl Med (2008) 1.20
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res (2006) 1.19
Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol (2010) 1.19
POTE paralogs are induced and differentially expressed in many cancers. Cancer Res (2006) 1.19
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood (2003) 1.17
High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin Cancer Res (2008) 1.16
Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. AJR Am J Roentgenol (2007) 1.16
Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol Cancer Ther (2002) 1.15
Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res (2002) 1.15
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res (2005) 1.14
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer (2009) 1.13
Impairment of reward-related learning by cholinergic cell ablation in the striatum. Proc Natl Acad Sci U S A (2003) 1.12
Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. J Neurooncol (2009) 1.11
CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res (2009) 1.10
Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths. Gene (2004) 1.10
Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog (2010) 1.10
Evolution and expression of chimeric POTE-actin genes in the human genome. Proc Natl Acad Sci U S A (2006) 1.09
Segregation and coactivation of developing neocortical layer 1 neurons. J Neurosci (2003) 1.08
NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cells. Cancer Res (2007) 1.08
High expression of a cytokeratin-associated protein in many cancers. Proc Natl Acad Sci U S A (2006) 1.08
Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res (2004) 1.07
A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer (2011) 1.06
New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother (2007) 1.06
A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther (2009) 1.05
Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss. Kidney Int (2013) 1.04
Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res (2006) 1.04
Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin Cancer Res (2011) 1.04
FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood (2007) 1.03
A model for obesity and gigantism due to disruption of the Ankrd26 gene. Proc Natl Acad Sci U S A (2007) 1.03
Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother (2006) 1.03
A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. J Immunother (2010) 1.03
Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells. J Immunol (2009) 1.02
PATE gene clusters code for multiple, secreted TFP/Ly-6/uPAR proteins that are expressed in reproductive and neuron-rich tissues and possess neuromodulatory activity. J Biol Chem (2008) 1.02
Ankrd26 gene disruption enhances adipogenesis of mouse embryonic fibroblasts. J Biol Chem (2011) 1.02
A primate-specific POTE-actin fusion protein plays a role in apoptosis. Apoptosis (2009) 1.02
Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding. Cancer Res (2011) 1.01
MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc Natl Acad Sci U S A (2002) 1.00
Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent. Hypertension (2010) 0.99